T. Rowe Price Investment Management, Inc., a registered investment adviser, initiated a new position in Eli Lilly and Company (NYSE:LLY) during Q4 2025, according to its most recent 13F filing with the Securities and Exchange Commission.
The institutional investor purchased 1,100,864 shares of the Healthcare company, valued at approximately $1.2B as of the filing date.
Eli Lilly and Company's stock currently trades at $1049.30 with a market capitalization of $906.5B.


